These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 27660080)
1. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Epperla N; Shah N; Hamadani M; Richardson K; Kapke JT; Patel A; Teegavarapu SP; Carrum G; Hari PN; Pingali SR; Karmali R; Fenske TS Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):672-678. PubMed ID: 27660080 [TBL] [Abstract][Full Text] [Related]
2. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Kapke JT; Epperla N; Shah N; Richardson K; Carrum G; Hari PN; Pingali SR; Hamadani M; Karmali R; Fenske TS Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):408-414. PubMed ID: 28756899 [TBL] [Abstract][Full Text] [Related]
3. Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. Mohyuddin GR; Clark AE; Roller J; Shune L; Lin T; Dunavin N; Dias A; Ganguly S; Abhyankar S; McGuirk J; Singh A Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):135-141. PubMed ID: 29278676 [TBL] [Abstract][Full Text] [Related]
4. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703 [TBL] [Abstract][Full Text] [Related]
6. Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma. Savani M; Gencturk M; Shanley R; Cayci Z; Wilke C; Warlick ED; He F; Janakiram M; Weisdorf DJ; Brunstein CG; Bachanova V Biol Blood Marrow Transplant; 2020 Feb; 26(2):272-277. PubMed ID: 31669174 [TBL] [Abstract][Full Text] [Related]
7. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Shadman M; Ahn KW; Kaur M; Lekakis L; Beitinjaneh A; Iqbal M; Ahmed N; Hill B; Hossain NM; Riedell P; Gopal AK; Grover N; Frigault M; Brammer J; Ghosh N; Merryman R; Lazaryan A; Ram R; Hertzberg M; Savani B; Awan F; Khimani F; Ahmed S; Kenkre VP; Ulrickson M; Shah N; Kharfan-Dabaja MA; Herrera A; Sauter C; Hamadani M Blood Cancer J; 2024 Jul; 14(1):108. PubMed ID: 38977682 [TBL] [Abstract][Full Text] [Related]
8. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757 [TBL] [Abstract][Full Text] [Related]
9. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Thiruvengadam SK; Hunter B; Varnavski A; Fakhri B; Kaplan L; Ai WZ; Pampaloni M; Huang CY; Martin T; Damon L; Andreadis CB Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):246-256.e2. PubMed ID: 33288485 [TBL] [Abstract][Full Text] [Related]
10. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Shah NN; Ahn KW; Litovich C; He Y; Sauter C; Fenske TS; Hamadani M Blood; 2021 Mar; 137(10):1416-1423. PubMed ID: 33120429 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192 [TBL] [Abstract][Full Text] [Related]
12. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669 [TBL] [Abstract][Full Text] [Related]
13. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Shadman M; Pasquini M; Ahn KW; Chen Y; Turtle CJ; Hematti P; Cohen JB; Khimani F; Ganguly S; Merryman RW; Yared JA; Locke FL; Ahmed N; Munshi PN; Beitinjaneh A; Reagan PM; Herrera AF; Sauter CS; Kharfan-Dabaja MA; Hamadani M Blood; 2022 Mar; 139(9):1330-1339. PubMed ID: 34570879 [TBL] [Abstract][Full Text] [Related]
14. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M; Calzada O; Xavier AC; Zhou Z; Hossain NM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Barta SK; Chhabra S; Lansigan F; Mehta A; Jaglal MV; Evens AM; Flowers CR; Cohen JB; Fenske TS; Hamadani M; Costa LJ Cancer; 2017 Nov; 123(22):4411-4418. PubMed ID: 28749548 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661 [TBL] [Abstract][Full Text] [Related]
16. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255 [TBL] [Abstract][Full Text] [Related]
18. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326 [TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Smith SD; Bolwell BJ; Rybicki LA; Kang T; Dean R; Advani A; Thakkar S; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW Bone Marrow Transplant; 2011 Feb; 46(2):262-6. PubMed ID: 20479706 [TBL] [Abstract][Full Text] [Related]
20. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]